Abstract
More than three decades have passed since the first virus-based vaccine was produced against the liver stages of malaria in 1984, and we have made significant progress since then. The most recent human clinical trials have shown that prime-boost heterologous immunization regimens consisting of viral-vectored malarial vaccines induce significant protection against controlled human malaria infections. In view of the fact that a first-generation malaria pre-erythrocytic stage candidate vaccine, RTS,S/AS01, was recently licensed by the European Medicines Agency, a new line of research has opened up for possible prime-boost heterologous immunization regimens utilizing both RTS,S and viral-vectored malarial vaccines. This chapter will review the research regarding the development of viral-vectored vaccines against the liver stages of malaria from small animal and nonhuman primate models to humans.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
